Press release
Investigation for Investors in BioAtla, Inc. (NASDAQ: BCAB) over potential Wrongdoing announced

An investigation on behalf of investors in BioAtla, Inc. (NASDAQ: BCAB) shares over potential wrongdoing at BioAtla, Inc.
Investors who purchased shares of BioAtla, Inc. (NASDAQ: BCAB) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain BioAtla, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. reported that its Net Loss increased from $95.4 million in 2021 to $106.48 million in 2022.
Shares of BioAtla, Inc. (NASDAQ: BCAB) declined from $4.31 per share in February 2023 to as low as $1.42 per share in October 2023.
Those who purchased shares of BioAtla, Inc. (NASDAQ: BCAB) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Investors in BioAtla, Inc. (NASDAQ: BCAB) over potential Wrongdoing announced here
News-ID: 3531401 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Alert: Investors who lost money with shares of Molina Healthcare, Inc. ( …
An investor, who purchased shares of Molina Healthcare, Inc. (NYSE: MOH), filed a lawsuit over alleged violations of Federal Securities Laws by Molina Healthcare, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Molina Healthcare, Inc. (NYSE: MOH) have certain options and for certain investors are short and strict deadlines running. Deadline: December 02, 2025. NYSE: MOH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
CTO Realty Growth, Inc. (NYSE: CTO) Long Term Investor Alert: Investigation of p …
An investigation on behalf of current long-term investors in shares of CTO Realty Growth, Inc. (NYSE: CTO) concerning potential breaches of fiduciary duties by certain directors and officers of CTO Realty Growth, Inc. was announced.
Investors who are current long term investors in CTO Realty Growth, Inc. (NYSE: CTO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a…
Lawsuit filed for Investors who lost money with shares of Marex Group plc (NASDA …
An investor, who purchased shares of Marex Group plc (NASDAQ: MRX), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Marex Group plc in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, have certain options…
LifeMD, Inc. (NASDAQ: LFMD) Investor Alert: Deadline in Lawsuit on October 27, 2 …
A deadline is coming up on October 27, 2025 in the lawsuit filed for certain investors of LifeMD, Inc. (NASDAQ: LFMD) over alleged securities laws violations by LifeMD, Inc.
Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and there are strict and short deadlines running. Deadline: October 27, 2025. LifeMD, Inc. (NASDAQ: LFMD) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for BioAtla
Synovial Sarcoma Market to Experience Notable Growth in Forecast Span by 2034, D …
The Key Synovial Sarcoma Companies in the market include - Advenchen Laboratories, Ipsen, Daiichi Sankyo, OncoTherapy Science, Foghorn Therapeutics, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., and others.
The Synovial Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Synovial Sarcoma pipeline products will significantly revolutionize the Synovial Sarcoma market dynamics.
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology,…
Leading companies in this space include Aadi Bioscience, Acrotech Biopharma, ADC …
Among the 7MM countries, the total Chondrosarcoma Market Size in the United States was ~USD 8.5 million in 2023 and is aniticipated to grow with a significant CAGR during the forecast period (2024-2034).
Emerging therapies like INBRX-109, TIBSOVO (ivosidenib), and others are anticipated to drive growth in the Chondrosarcoma market over the coming years.
DelveInsight's newly released report, "Chondrosarcoma - Market Insights, Epidemiology, and Market Forecast 2034", provides a comprehensive overview of…
Synovial Sarcoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, …
DelveInsight's, "Synovial Sarcoma- Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Synovial Sarcoma pipeline includes over 15 major…
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveIns …
The Osteosarcoma market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight's latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.
DelveInsight's "Osteosarcoma - Market Insight, Epidemiology, And Market Forecast - 2032 [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] report offers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United…
Investigation announced for Investors who lost money with shares of BioAtla, Inc …
An investigation was announced for investors of BioAtla, Inc. (NASDAQ: BCAB) shares over potential securities laws violations by BioAtla, Inc. in connection with certain financial statements.
Investors who purchased shares of BioAtla, Inc. (NASDAQ: BCAB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of BioAtla, Inc.…
Synovial Sarcoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging The …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Synovial Sarcoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Synovial Sarcoma Pipeline Insight, 2023" report…